Leading global provider of healthcare products Covidien announced the opening of its China Technology Center and Research and Development facility in Shanghai.
"The establishment of this R&D facility in Shanghai strengthens Covidien’s continued commitment to provide innovative new products. It will also help healthcare providers worldwide improve patient care and extend healthcare delivery to more people and more places," said JosÃ© E. Almeida, Chairman, President and CEO of Covidien.
China is a key market in our global strategy, and this investment is a reflection of our strategic initiative. With a total investment of $45 million over a three year period, the China Technology Center will employ more than 300 people.
The facility spans more than 100,000 square feet, houses 17 laboratories and has state-of-the-art surgical and simulation suites that enables healthcare professionals to be actively involved in medical device design and development process.
Shanghai unit will provide a focal point to develop local Chinese talent and groom the next generation of medical innovators for the industry.
Dong Wu, Vice President, China RA&D Covidien said, “By collaborating closely with local medical experts who use our products, we can tailor devices to meet the demands of other emerging markets and China.” Mr. Covidien also said, “We recognize the immense potential of basing an R&D facility in Shanghai. This location will help us tap into internationally renowned experts based here in China, including the world-class engineering talent. We believe this collaboration will drive innovation in China and across the emerging markets healthcare landscape.”
Covidien is a global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through the clinical leadership and excellence. The company has 43,000 employees worldwide in over 65 countries and its products are sold in more than 140 countries.